AstriVax Therapeutics

Biotechnology ResearchFlanders, Belgium11-50 Employees

AstriVax Therapeutics is a clinical-stage biopharmaceutical company focused on immunotherapies for virus-driven cancers and related chronic infections. Its Launch-iT platform seeks to generate durable, antigen-specific T-cell responses capable of clearing virus-infected cells, supported by a manufacturing process designed for scalability and tech transfer. The lead program targets human papillomavirus 16 (HPV16), a major cause of virus-driven cancers such as cervical cancer and certain head and neck cancers. The company also investigates the platform’s potential for persistent HPV infections and for applications beyond oncology in autoimmune diseases where viral infections are implicated.

Based in Heverlee, Flanders, Belgium, the firm operates as a small to mid-sized biotechnology company. In June 2025, Dieter Weinand was appointed as Chair of the Board of Directors. The organization continues to advance its platform toward clinical proof-of-concept for HPV-related indications and to evaluate expansion into additional HPV-driven cancers.

Sign up for free to view info

Email Format Employee directory